Drug Price Transparency Rule Tees Up Constitutional Concerns
Trump Administration addresses concerns that the rule violates the First Amendment and exceeds its statutory authority in the final rule, which is strongly opposed by biopharma.
Trump Administration addresses concerns that the rule violates the First Amendment and exceeds its statutory authority in the final rule, which is strongly opposed by biopharma.